All Stories

CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing

CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ahead with dose escalation.

May 8, 2025 - 23:17
 0
CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing
CRISPR Therapeutics has reported reductions in triglycerides and LDL cholesterol of more than 80% after a single dose of its in vivo liver editing prospect CTX310, encouraging the company to forge ahead with dose escalation.
Read More

Tags:

Previous Article

Charles River launches strategic review and shakes up board amid regulatory unce...

Next Article

Marea rises toward phase 2b after showing antibody cuts remnant cholesterol

Related Posts

GE HealthCare rolls out new AI-equipped SPECT/CT nuclear medicine scanner

GE HealthCare rolls out new AI-equipped SPECT/CT nuclea...

May 8, 2025  0

New NIH grant rules override the Civil Rights Act of 1964, barring recipients from DEI activities

New NIH grant rules override the Civil Rights Act of 19...

Apr 21, 2025  0

Boston Scientific plans to make ground despite $200M in tariff headwinds

Boston Scientific plans to make ground despite $200M in...

Apr 24, 2025  0